BML Capital Management LLC Buys 56,643 Shares of CalciMedica, Inc. (NASDAQ:CALC)

BML Capital Management LLC grew its stake in CalciMedica, Inc. (NASDAQ:CALC) by 63.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 145,424 shares of the company’s stock after purchasing an additional 56,643 shares during the quarter. CalciMedica makes up approximately 0.3% of BML Capital Management LLC’s investment portfolio, making the stock its 29th largest holding. BML Capital Management LLC owned approximately 2.56% of CalciMedica worth $416,000 as of its most recent SEC filing.

Separately, Hudson Bay Capital Management LP acquired a new position in shares of CalciMedica in the third quarter valued at about $432,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of CalciMedica in a research note on Monday, April 1st. Jonestrading assumed coverage on shares of CalciMedica in a research note on Friday, February 16th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, Oppenheimer restated an “outperform” rating and issued a $14.00 price target on shares of CalciMedica in a research note on Monday, April 1st.

CalciMedica Stock Performance

CALC stock opened at $4.59 on Wednesday. The company has a market capitalization of $49.30 million, a PE ratio of -0.18 and a beta of 1.61. CalciMedica, Inc. has a 52 week low of $1.75 and a 52 week high of $8.59. The company’s 50-day simple moving average is $4.28 and its 200 day simple moving average is $3.81.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.77. On average, analysts forecast that CalciMedica, Inc. will post -2.04 EPS for the current year.

CalciMedica Profile

CalciMedica, Inc, a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.